Value of the 14-gene molecular assay in efficacy assessment of neoadjuvant chemoimmunotherapy for non-small cell lung cancer.

Front Mol Biosci · 2025 · PMC12286801 · PMID 40708839

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

These findings revealed a notable trend: patients classified under higher 14-gene risk stratification exhibited reduced TIL infiltration and lower TLS positivity.

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.